Roche has agreed to acquire oncology research platform Flatiron in a deal that valued it at $2.15bn, giving GV what would be its fifth latest life sciences exit since the start of November.

US-based oncology research technology provider Flatiron Health is set to become the latest of GV’s life sciences-focused portfolio companies to net it an exit, after agreeing to a $1.9bn acquisition by pharmaceutical firm Roche last week. Flatiron has developed an oncology research software platform that stores data from electronic health records. It works with more…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.